Trial Profile
A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in ≥ 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs MVA-BN RSV (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacodynamics
- Sponsors Bavarian Nordic
- 29 Jul 2020 Results assessing immune response in adults to identify the optimal MVA-BN-RSV dose and vaccination schedule, published in the Journal of Infectious Diseases.
- 22 Jan 2019 Status changed from active, no longer recruiting to completed.
- 22 Nov 2018 Planned End Date changed from 1 Aug 2018 to 1 Dec 2018.